A application of radiofrequency ablation in the palliative treatment of bone metastases

Feng YU,Qing ZHANG,Hai-tao ZHAO,Li-hui XU,Xiao-hui NIU

DOI: https://doi.org/10.3969/j.issn.2095-252X.2014.04.007

2014-01-01

Abstract:Objective To investigate the safety and effectiveness of radiofrequency ablation ( RFA ) in the treatment of bone metastases. Methods From November 2008 to December 2012, 19 patients with bone metastases were treated with RFA in our department. There were 10 males and 9 females with an average age of 57 years old ( range;41-76 years ). Lung carcinoma was the most common primary tumor ( n=11 ), followed by kidney carcinoma ( n=2 ), breast carcinoma ( n=1 ), thyroid carcinoma ( n=1 ), rectal carcinoma ( n=1 ), gastric carcinoma ( n=1 ), hepatocellular carcinoma ( n=1 ) and unknown carcinoma ( n=1 ). There were totally 21 lesions in the 19 patients, including 9 lesions in the femur, 6 lesions in the pelvis, 5 lesions in the humerus and 1 lesion in the tibia. Curettage and reconstruction after the RFA were performed for 16 lesions. Percutaneous RFA was performed for 5 lesions, and 3 of them in the femoral shaft were ifxed with intramedullary nails. During the follow-up, the pain scores and function scores were used to evaluate the effects and check the recurrence and the safety of the surgery. There were 2 kinds of evaluation methods. ( 1 ) The preoperative and postoperative pain scores were compared ( numerical rating scale ). ( 2 ) The function evaluation of the patients whose survival time was more than 6 months was performed ( the Musculoskeletal Tumor Society MSTS rating scale ). Results The mean follow-up period was 10 months (range;1-32 months ) and the mean survival time was 9.7 months ( range;1-32 months ). Fifteen patients were dead. The mean pain score was 8.1 points before the surgery and 2.2 points and 2.7 points at 1 week and 3 months after the surgery respectively, and there were statistically signiifcant differences before and after the surgery ( P<0.01 ). Local pain recurred in 1 patient at 6 months after the ablation with the pain score of 7 points, who received oral analgesic but died 11 months later due to the progress of primary tumors. One patient had thermal damage around the skin adjacent to the tourniquet during the surgery and 1 patient developed wound necrosis after the surgery. The function evaluation was performed in 12 patients whose survival time was more than 6 months, and the excellent and good rate was 83.3%. Conclusions The RFA is a safe and effective approach in the palliative treatment of bone metastases. The local pain can be relieved and the development of bone metastases can be controlled.